Pell's lentiviral-based gene-edited immune cell therapy

Pell's lentiviral-based gene-edited immune cell therapy is an investigational cell therapy involving immune cells that have been genetically modified ex vivo using a lentiviral vector system. The therapy is designed to correct or enhance immune cell function by introducing targeted genes into patient immune cells, typically T cells, using lentiviral gene delivery technology. These gene-edited immune cells are then infused back into the patient as a treatment, with the goal of addressing hematologic malignancies such as large B-cell lymphoma, follicular lymphoma, and primary mediastinal large B-cell lymphoma. The mechanism centers on the modification of immune cells to either restore normal function in cases of genetic immune deficiency or to enhance antitumor activity, as in CAR-T therapies. It is primarily developed by Pell Bio-Med Technology and is currently under investigation in clinical trials, notably including a long-term follow-up study and early-phase trials in Taiwan[3][2]. This modality builds upon established lentiviral gene therapy, which has demonstrated safety and efficacy in similar settings, providing stable gene transfer and persistent therapeutic effects in hematopoietic cells[1][5][6].

Brand names

Pell's lentiviral-based gene-edited immune cell therapy

Other names

Pell's lentiviral-based gene-edited immune cell therapy